Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015674 (
chronic fatigue syndrome
)
2,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study investigated the relative rates of personality disturbance in
chronic fatigue syndrome
(
CFS
). Individuals who met the CDC criteria for
CFS
were compared to two other fatiguing illness groups, mild multiple sclerosis and
depression
, as well as sedentary healthy controls. Subjects were administered a structured psychiatric interview to determine Axis I psychiatric disorders and two self-report instruments to assess Axis II personality disorders and the personality trait of neuroticism. The depressed group had significantly more personality disorders and elevated neuroticism scores compared with the other three groups. The
CFS
and MS subjects had intermediary personality scores which were significantly higher than healthy controls. The
CFS
group with concurrent depressive disorder (34% of the
CFS
group) was found to account for most of the personality pathology in the
CFS
sample. The results are discussed in the context of the relationship between personality variables and fatiguing illness.
...
PMID:Personality dimensions in the chronic fatigue syndrome: a comparison with multiple sclerosis and depression. 873 61
Because of the striking similarity of the clinical manifestations produced by use of the drug reserpine and seen in patients with the
chronic fatigue syndrome
(
CFS
), we theorized that
CFS
was a disorder of reduced central sympathetic drive. Because of the pharmacology of control of this central sympathetic system, we further postulated that
CFS
symptoms would respond quickly to low dose treatment with a monamine oxidase inhibitor. To test these hypotheses, we designed a randomized, double blind placebo controlled study using phenelzine. No patient in the trial had a diagnosis of lifetime or current psychiatric disorder and none had depressed mood in the range of clinically depressed patients on a paper and pencil test of
depression
. Patients in the placebo group received placebo for 6 weeks while those in the drug treatment group were treated in three 2-week segments-placebo, 15 mg phenelzine every other day, and then 15 mg daily. This treatment regimen produced a significant pattern of improvement compared to worsening in 20 self report vehicles of
CFS
symptoms, illness severity, mood or functional status. Thus the data support our hypothesis of reduced sympathetic drive, although an alternative hypothesis of pain alleviation is also possible. The study design also allowed us to evaluate patients for a placebo effect: no evidence for this was found, suggesting that
CFS
is not an illness due to patients' being overly suggestible.
...
PMID:Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. 874 43
Because
depression
is commonly observed in the
chronic fatigue syndrome
(
CFS
), the present study sought to determine whether the symptom pattern is similar to that seen in clinically depressed subjects (DEP). Individuals with multiple sclerosis (MS) were chosen as an additional comparison group because MS is a fatiguing illness of known organic etiology. The Beck
Depression
Inventory (BDI) was used to compare categories of depressive symptomatology. Absolute scores on the BDI were higher for the depressed group on mood and self-reproach symptoms, but were not higher than the
CFS
group on somatic and vegetative items. Analysis of symptoms as a percentage of total BDI score revealed no significant differences in mood or vegetative items among the three groups. The
CFS
and MS groups exhibited a significantly lower percentage of self-reproach symptoms than DEP, whereas the DEP group showed a lower percentage of somatic symptoms than the
CFS
and MS groups.
...
PMID:Depression in fatiguing illness: comparing patients with chronic fatigue syndrome, multiple sclerosis and depression. 883 50
Data were gathered regarding the associates of
chronic fatigue syndrome
(
CFS
) with: (1) speed of cognitive processing, (2) motor speed, (3) ability to sustain attention, and (4) mood. Patients were given a brief neuropsychological test battery before and after double-blind treatment with terfenadine or placebo and completed a daily mood rating scale (Positive and Negative Affect Schedule) during the study.
CFS
patients exhibited slower cognitive processing and motor speed and lower positive affect, as compared to data reported from previous studies of healthy subjects and other patient groups; however,
CFS
patients did not exhibit deficits in sustained attention in comparison to other groups. The
CFS
patients' ability to attend to verbal versus figural stimuli and mood ratings were different from those reported in studies of patients with
depression
. Because of methodological limitations, these findings are preliminary, but they encourage further assessment of cognitive dysfunction and mood in
CFS
.
...
PMID:An assessment of cognitive function and mood in chronic fatigue syndrome. 883 81
Traditional aetiological models in neuropsychiatry have placed little emphasis on the abnormal behavioural responses (decreased psychomotor activity, anorexia, weight loss, decreased social exploration and sexual behaviour, impaired cognitive function and increased somnolence) that are common to both psychiatric syndromes, notably
depression
, and the illness behaviour of sick animals. In recent years, the possible role of cytokines, as mediators of not only the immunological and metabolic responses to infection and inflammation but also a co-ordinated behavioural response, has been described. Further, a range of possible mechanisms for these effects has been postulated, notably involving corticotropin releasing factor (CRF) and prostaglandins of the E series (PgE) with the central nervous system (CNS). Here we outline a series of human clinical conditions where neuropsychiatric syndromes co-occur with a host response to infection or inflammation. These may be characterized by cytokine production (e.g. acute, recurrent and chronic viral illness, systemic autoimmune diseases and
chronic fatigue syndrome
). Other clinical situations characterized by exposure to or in vivo production of cytokines (e.g. treatment of chronic infections and malignancies, progression and/or recurrence of malignancies) are also discussed. We postulate that the stereotyped behavioural repertoire observed is mediated by cytokine-dependent mechanisms within the CNS. Systematic studies of the behavioural responses of such patient groups are suggested, noting specifically correlations between the time course and severity of immune and neuroendocrine and behavioural responses and dose-response effects.
...
PMID:Are cytokines associated with neuropsychiatric syndromes in humans? 884 62
Chronic fatigue syndrome
(
CFS
) is an illness characterized by disabling fatigue associated with complaints of fevers, sore throat, myalgia, lymphadenopathy, sleep disturbances, neurocognitive difficulties, and
depression
. A striking feature of
CFS
is its sudden onset following an acute, presumably viral, illness and the subsequent recurrent "flu-like" symptoms. It has been speculated that both
CFS
and debilitating chronic fatigue (CF) that does not meet strict criteria for
CFS
may be the direct or indirect result of viral infections. We therefore tested 548 chronically fatigued patients who underwent a comprehensive medical and psychiatric evaluation for antibodies to 13 viruses. Our objectives were to compare the seroprevalence and/or geometric mean titer (GMT) of antibodies to herpes simplex virus 1 and 2, rubella, adenovirus, human herpesvirus 6, Epstein-Barr virus, cytomegalovirus, and Cox-sackie B virus, types 1-6 in patients with CF to healthy control subjects. Other goals were to determine if greater rates of seropositivity or higher GMTs occurred among subsets of patients with
CFS
, fibromyalgia, psychiatric disorders, a self-reported illness onset with a viral syndrome, and a documented temperature > 37 degrees C on physical examination. Differences in the seroprevalence or GMTs of antibodies to 13 viruses were not consistently found in those with CF compared with control subjects, or in any subsets of patients including those with
CFS
, an acute onset of illness, or a documented fever. These particular viral serologies were not useful in evaluating patients presenting with CF.
...
PMID:Viral serologies in patients with chronic fatigue and chronic fatigue syndrome. 889 37
People with
chronic fatigue syndrome
(
CFS
) complain of difficulties with concentration and memory yet studies suggest that they do not suffer gross deficits in cognitive functioning. Depressed patients make similar cognitive complaints, and there is symptomatic overlap between
CFS
and
depression
. Cognitive complaints and depressed mood are positively correlated in
CFS
patients but, except on tasks which are particularly sensitive to
depression
, cognitive performance and
depression
are not. The inconsistency between cognitive complaints and results of tests of cognitive functioning resembles that found in other subject groups and may be due in part to the inappropriate use of laboratory memory tests for assessing "everyday" cognitive functioning. Even when cognitive capacity is intact, cognitive performance may be affected by factors such as arousal, mood, and strategy. In
CFS
patients, everyday cognitive tasks may require excessive processing resources leaving patients with diminished spare attentional capacity or flexibility.
...
PMID:Research on cognitive complaints and cognitive functioning in patients with chronic fatigue syndrome (CFS): What conclusions can we draw? 891 Feb 43
We studied the effects of exercise on motor evoked potentials (MEPs) elicited by transcranial magnetic stimulation (TMS) in 18 normal (control) subjects, 12 patients with
chronic fatigue syndrome
, and 10 depressed patients. Subjects performed repeated sets of isometric exercise of the extensor carpi radialis muscle until they were unable to maintain half maximal force. MEPs were recorded before and after each exercise set and for up to 30 minutes after the last set. The mean amplitude of MEPs recorded from the resting muscle immediately after each exercise set was 218% of the mean pre-exercise MEP amplitude in normal subjects, 126% in chronic fatigue patients, and 155% in depressed patients, indicating postexercise MEP facilitation in all three groups. The increases in the patient groups, however, were significantly lower than normal. The mean amplitudes of MEPs recorded within the first few minutes after the last exercise sets in all three groups were approximately half their mean pre-exercise MEP amplitudes. This postexercise MEP
depression
was similar in all groups. We conclude that postexercise cortical excitability is significantly reduced in patients with
chronic fatigue syndrome
and in depressed patients compared with that of normal subjects.
...
PMID:Decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome or depression. 896 Jul 19
This article reviews the
chronic fatigue syndrome
(
CFS
), a disorder whose etiology is unknown. The diagnostic criteria proposed in 1994 by the CDC and the International
Chronic Fatigue Syndrome
Study Group are introduced. In contrast to widespread belief, there are no laboratory tests available to underpin the diagnosis of
CFS
; the diagnosis is made solely on the basis of clinical criteria. In the differential diagnosis, the exclusion of other conditions that can cause chronic fatigue, such as neuropsychiatric or sleep disorders, is of critical importance. In this context, the question as to whether
CFS
is a clinical entity that can be differentiated from psychiatric diagnoses, such as
depression
, somatoform disorder, or neurasthenia, is discussed. At the moment, there is no specific therapy for
CFS
. Therefore, therapeutic approaches are limited to symptomatic management of the concomitant sleep disturbances, pain, or psychiatric symptoms, such as
depression
. Patients may benefit from cognitive behavioral therapy, as this may help then to identify and exclude factors contributing to and maintaining chronic fatigue. An integrated medical and psychological approach should be adopted, with the aim of preventing significant secondary negative results of the illness, such as interpersonal conflicts or chronic disability.
...
PMID:[Chronic fatigue syndrome. Definition, diagnostic measures and therapeutic possibilities]. 973 40
The relationship between markers of immune function and
chronic fatigue syndrome
(
CFS
) is controversial. To examine the relationship directly, 43 subjects with
CFS
entering a randomized controlled trial of a nonpharmacological treatment for
CFS
gave samples for immunological analysis before and after treatment. Percentage levels of total CD3+ T cells, CD4 T cells, CD8 T cells, and activated subsets did not differ between
CFS
subjects and controls. Naive (CD45RA+ RO-) and memory (CD45RA- RO+) T cells did not differ between subjects and controls. Natural killer cells (CD16+/CD56+/CD3-) were significantly increased in
CFS
patients compared to controls, as was the percentage of CD11b+ CD8 cells. There were no correlations between any immune variable and measures of clinical status, with the exception of a weak correlation between total CD4 T cells and fatigue. There was a positive correlation between memory CD4 and CD8 T cells and
depression
scores and a negative correlation between naive CD4 T cells and
depression
. No immune measures changed during the course of the study, and there was no link between clinical improvement as a result of the treatment program and immune status. Immune measures did not predict response or lack of response to treatment. In conclusion, we have been unable to replicate previous findings of immune activation in
CFS
and unable to find any important associations between clinical status, treatment response, and immunological status.
...
PMID:Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation. 900 46
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>